|
GSBPL's IN HOUSE R&D unit is now a recognized entity
Ministry of Science & Technology, GOI has accorded recognition on our In-House R&D unit situated at Gummidipundi, Chennai.
|
New Office
New Office
Our corporate office from Mylapore has been shifted to Kodambakkam on 24th Jun'10. The address is
Old No.5, New No.13/A3 Sai Nikethan Circular Road,
United India Colony, Kodambakkam, Chennai - 600 024
Tel.No.24722244 / 24816161
Fax No.24722233
|
Indonesia NRA Inspection
Indonesia NRA Inspection
Indonesia NRA has conducted the inspection of our factory from 10th May’10 to 12th May’10 for prequalification / purchase of products for using in Indonesia.
|
Chairman’s interview in the South Asian Times
India – CIS Pharma Business Meet
India – CIS Pharma Business Meet
Our Executive Director – Mr. E.S. Chandrasekaran and our Director – Business Development participated the India – CIS Pharma Business Meet organized by Pharmexcil from 19th – 21st July’10 at Mumbai and had detailed discussion with NRA / Agents of Moldova, Kazakhstan, Belarus, Uzbekistan, Russia and Ukraine.
|
Earth Day Celebration - 5/4/2009 3:52:11 AM
Earth Day Celebration
5/4/2009 3:52:11 AM
Earth Day Celebration at Factory on the 28th April 2009. Oath taken by all the officials and workers.
The movie "An inconvenient truth" was screened to drive home the fact that mother earth needs to be protected from the onslaught by mankind that has culminated in global warming.
The employees pledged to refrain from activities that would add to global warming.
|
Gsbpl Quality Health care -
9/24/2008 1:03:15 AM
Gsbpl Quality Health care
9/24/2008 1:03:15 AM
The company aims at "Quality Health care for all" and to make available the much needed immunologicals at a lesser cost to the masses in India. For which, high-end equipments imported from various parts of the world are used in the production. Manufacturing and quality control on par with international Standards. In India, GSBPL has judicial developmental partnerships, new products in pipeline, cost - effective and successful marketing strategies for vaccine field.
|
Vaccine Technology
Vaccine Technology
We introduce ourselves as Green Signal Bio Pharma Private Ltd,a State-of-the-art manufacturing facility for human vaccines,at Gummidipoondi ,Tamilnadu
The increased incidence of disease associated with HIV infection highlights the crucial role of the immune response in susceptibility to tuberculosis has stimulated renewed efforts to develop improved vaccines.Vaccine targets include:
|
Prevention of infection in naïve individuals.
Prevention of re-activation in individuals harbouring latent infection.
Prevention of relapse by immunotherapy in tuberculosis patients.
|
|
GSBPL has successfully launched it's first product of BCG 10(Freeze dried),a safe and effective bacterial vaccine for immunization against tuberculosis.
|
|
BCG vaccine
|
They have largely been targetted against viral and bacterial pathogens,as well as some bacterial toxins and,to a lesser extent parasitic agents such as malaria..The term "traditional" refers to those vaccines whose development predated the advent of recombinant DNA technology.These can be categorized as below:
|
Live,attenuated bacterial strain of Mycobacterium tuberculosis e.g Bacillus Calmette-Guerin(BCG) used to active immunization against tuberculosis.
|
The product is readily available for the global market with a capacity of approximately 1 million vials of 10 doses per month,The most important feature of our BCG vaccine is that the seed strain used for production is of Danish 1331 which is the same strain successfully being used for several decades.The vaccine
Is manufactured in a cGMP compliant production unit conveniently located in the outskirts of Chennai city.This unit is exclusively dedicated to BCG vaccine alone.
|
Salient features of our BCG vaccine
|
Manufactured as per cGMP standards at our new state-of-the-art facility.
|
Seed strain used is Danish 1331.
|
As per I.P/B.P/E.P/U.S.P
|
Clinically proven for safety and efficacy.
|
Conducted randomized multi-centric clinical studies.
|
With V V M (Vaccine-Vial-Monitor) for assurance of quality.
|
CFU as per WHO standards.
|
The application of vaccine technology forms a core element of modern medicinal endeavour.It plays a central role,not only in human but also in vetenary medicine and represents the only commonly employed prophylactic( i.e preventive) approach undertaken to control many infectious diseases.The current(global) vaccine market stands
At in excess of $3 billion.Immunization programmes ,particularly those undertaken on a multi-national scale,have served to reduce dramatically the incidence of killer/disabling diseases,such as small pox,polio and tuberculosis.
Continued /increased emphasis upon the implementation of such immunization programmes is likely.This is true not only of poorer world regions,but also amongst the most affluent nations.An estimated 500,000 adults die annually in the USA from conditions that could have been prevented by vaccination.These include pneumococcal pneumonia,influenza and hepatitis B.
Vaccination seeks to exploit the natural defense mechanisms conferred upon us by our immune systems.A vaccine contains a preparation of antigenic components consisting of,derived from or related to a pathogen.In most instances,upon vaccination administration,both hormonal and cell-mediated arms of the immune system are activated.The long-term immunological protection induced will normally prevent subsequent establishment of an infection by the same or antigenically-related pathogens.
While some vaccines are active when administered orally,more are administered parenterally.Normally ,an initial dose administration followed by subsequent administration of one or more repeat doses over an appropriate time scale.Such booster doses serve to maximize the immunological response.
|
|
|
